In the second phase of clinical trials of a drug against chronic myeloid leukemia in patients with amyotrophic lateral sclerosis, a team of scientists at Kyoto University was able to suppress the progression of the disease in half of the cases.
The Japanese Kyodo News Agency indicates that the results of the first phase of clinical trials conducted by Kyoto University scientists using the so-called iPS test began in 2019, which included cultivating induced stem cells (iPS cells) from the skin of patients, after which they were converted into motor neurons to restore Production of amyotrophic lateral sclerosis. They then tested more than a thousand drugs on the resulting motor neurons, eventually choosing bosutinib, which is used to treat chronic myeloid leukemia.
Scientists confirm that, based on the results of the first phase of clinical tests, the progression of the disease was suppressed in 5 out of nine patients.
It is noteworthy that the second phase of clinical testing began in the spring of 2022 with the participation of 26 patients who took Bosutinib over a period of 24 weeks.
According to scientists, at least 13 patients out of the 26 observed had suppressed disease progression. Scientists now plan to apply for approval of the drug to treat amyotrophic lateral sclerosis (ALS) and begin late-stage testing.
With half of patients responding, further testing could lead to a new treatment option.
ReplyDelete